TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development
November 13, 2024 07:00 AM Eastern Standard Time SOUTH SAN FRANCISCO–(BUSINESS WIRE)–TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced the close of an oversubscribed $84 million…